These findings demonstrate that blocking E-selectin with uproleselan mobilizes cancer cells over a long period of time, sustains the presence of tumor cells in circulation, inhibits their reentry into the BM, and thereby provides a longer window to target these cells in the circulation, sensitizing them to chemotherapy thus longer exposure to chemotherapy, and as a result significant reduction of the tumor burden [23,45]. The gene discussed is SELE; the disease is cancer.